Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cardiovascular Systems, Inc. (CSII)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.88-0.08 (-0.24%)
At close: 4:00PM EDT
33.88 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement

Cardiovascular Systems, Inc.

1225 Old Highway 8 Northwest
Saint Paul, MN 55112-6416
United States
651 259 1600
http://www.csi360.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees780

Key Executives

NameTitlePayExercisedYear Born
Mr. Scott Raymond Ward B.Sc., M.S., MSChairman, Pres & CEO1.46MN/A1960
Mr. Jeffrey S. PointsChief Financial Officer682.69kN/A1977
Ms. Rhonda J. RobbChief Operating Officer954.83kN/A1968
Mr. Alexander RosensteinGen. Counsel & Corp. Sec.614.96kN/A1972
Dr. Ryan D. Egeland M.D., Ph.D.Chief Medical Officer522.93kN/A1975
Mr. John M. HastingsExec. VP of Operations & TechnologyN/AN/A1980
Mr. John E. NielsenVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Sandra M. SedoChief Compliance OfficerN/AN/A1964
Mr. David S. WhitescarverVP of Corp. Devel. & Intellectual PropertyN/AN/A1958
Mr. Stephen J. RempeChief HR OfficerN/AN/A1973
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.

Corporate Governance

Cardiovascular Systems, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 10; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement